Dr Frederick R Ellwanger Iii, MD | |
749 Wild Oak Ln Nw, Calabash, NC 28467-1939 | |
(910) 575-7678 | |
(910) 575-7678 |
Full Name | Dr Frederick R Ellwanger Iii |
---|---|
Gender | Male |
Speciality | Radiology - Radiation Oncology |
Location | 749 Wild Oak Ln Nw, Calabash, North Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1043319098 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2085R0001X | Radiology - Radiation Oncology | 18944 (North Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Frederick R Ellwanger Iii, MD 749 Wild Oak Ln Nw, Calabash, NC 28467-1939 Ph: (910) 575-7678 | Dr Frederick R Ellwanger Iii, MD 749 Wild Oak Ln Nw, Calabash, NC 28467-1939 Ph: (910) 575-7678 |
News Archive
Fine wrinkles, deeper creases, saggy areas around the mouth and neck - the sights in the mirror that make baby boomers wince - are not inevitable. They result from a structural breakdown inside the skin that some existing treatments effectively counteract by stimulating the growth of new, youthful collagen, University of Michigan scientists say.
Half of Australian adults and 63 per cent of Australians on a higher income believe 15 to 17 year olds should be allowed to consume alcohol under parental supervision at home, according to the latest MBF Healthwatch survey.
"With donor money to fight HIV and AIDS falling, spending in sub-Saharan Africa must be targeted to get the best results," Bjorn Lomborg, director of the Copenhagen Consensus Center, writes in the Guardian's "Poverty Matters" blog, noting, "Sub-Saharan Africa has 10 percent of the world's population but is home to 70 percent of those living with HIV and AIDS."
In a new World Economic Forum-Ipsos survey of nearly 20,000 adults from 27 countries, 74% say they would get a vaccine for COVID-19. This majority might still fall short of the number required to beat COVID-19, with less than a majority (37%) who are firm in their view. More than half (59%) do not expect that one will be available before the end of this year.
Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced issuance of a new U.S. patent for its lead compound, GLYX-13.
› Verified 9 days ago